Your browser is no longer supported. Please, upgrade your browser.
Pharming Group N.V.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand63.88M Perf Week2.59%
Market Cap709.09M Forward P/E- EPS next Y- Insider Trans- Shs Float62.90M Perf Month-3.39%
Income- PEG- EPS next Q- Inst Own0.30% Short Float0.00% Perf Quarter-13.28%
Sales172.44M P/S4.11 EPS this Y- Inst Trans- Short Ratio0.01 Perf Half Y-25.60%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range10.80 - 21.99 Perf YTD-26.95%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-49.52% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low2.78% ATR0.27
Employees262 Current Ratio- Sales Q/Q-26.90% Oper. Margin- RSI (14)43.60 Volatility1.67% 1.15%
OptionableNo Debt/Eq- EPS Q/Q-16.30% Profit Margin- Rel Volume0.33 Prev Close11.18
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.97K Price11.10
Recom- SMA20-1.66% SMA50-6.70% SMA200-15.35% Volume977 Change-0.72%
Jul-20-21 01:00AM  
Jul-01-21 10:35AM  
Jun-23-21 01:00AM  
Jun-18-21 01:00AM  
Jun-04-21 01:00AM  
Jun-01-21 01:00AM  
May-19-21 04:31PM  
May-17-21 01:00AM  
May-13-21 01:00AM  
Apr-22-21 01:00AM  
Apr-07-21 04:00PM  
Apr-06-21 05:30PM  
Mar-23-21 02:00AM  
Mar-16-21 08:10AM  
Mar-11-21 01:00AM  
Mar-04-21 01:00AM  
Mar-02-21 01:00AM  
Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has development collaboration and license agreement with Novartis. Pharming Group N.V. is headquartered in Leiden, the Netherlands.